We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Research Examines Gene Therapy To Treat Uterine Fibroids

By LabMedica International staff writers
Posted on 23 Feb 2009
Investigators have begun using gene therapy to treat uterine fibroids, a condition that is four times more prevalent in African American women than in women from other ethnic groups in the United States. More...


In an article published in the January 2009 issue of the Fertility and Sterility, the journal of the American Society for Reproductive Medicine, Ayman Al-Hendy, M.D., professor and vice chair of the department of obstetrics and gynecology at Meharry Medical College (Nashville, TN, USA) described his findings. "This condition is a major issue of health disparity because it puts African American women at a huge disadvantage during their most productive years,” said Dr. Al-Hendy.

Uterine fibroids occur in nearly 40% of reproductive age women beginning in their mid-20s and continuing until menopause. The symptoms are often debilitating and include excessive vaginal bleeding, anemia, fatigue, and lack of energy. According to Dr. Al-Hendy, women who suffer from uterine fibroids may lose time from work, have higher medical expenses, and frequently need advanced medical treatment in order to become pregnant, all things that cause both emotional and economic difficulties for families.

Dr. Al-Hendy's research, conducted on experimental animals, revealed that gene therapy treatment could be confined to the benign fibroid tumor without causing damage to the rest of the uterus. Current treatments usually include invasive surgeries that may result in greater scarring and infertility. While further experimentation is needed, Dr. Al-Hendy believes his new approach will offer hope and relief to millions of women.

"If we can achieve our research goal, women will see a greater decrease in their symptoms without the need for surgery and be able to preserve their fertility potential at same time,” Dr. Al-Hendy's noted. His research will continue safety testing in experimental animals; the next step will be to move toward clinical trials.

Meharry Medical College's Center for Women's Health Research is also developing other nonsurgical treatments for uterine fibroids. Clinical trials are currently being conducted using nutritional supplements and other pharmaceuticals for alternative noninvasive treatment for uterine fibroids.

Related Links:
Meharry Medical College




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.